“…Although preclinical studies support CBD's promise as a potential treatment for AD, there are several limitations and areas for future research to address. First, despite encouraging results from preclinical studies, to date, no human randomized control trials (RCTs) have investigated the efficacy and safety of CBD in treating AD [2,11,26,[156][157][158][159][160][161][162][163][164][165][166][167][168]. Second, the optimal dosage, administration route, formulation, and treatment duration of CBD for achieving effective management of AD is unclear, and determining this remains challenging [38,[158][159][160]162,164,165,[169][170][171].…”